2.40

1.69% 0.04

After Hours: 2.39 -0.010 -0.42%

Zyversa Therapeutics Inc (ZVSA)

Overview News Price History Financials Why ZVSA Down? Discussions Forecast

Zyversa Therapeutics Inc stock is traded at $2.40, with a volume of 20,282. It is up +1.69% in the last 24 hours and down -13.04% over the past month. ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Previous Close:

$2.36

Open:

$2.3399

24h Volume:

20,282

Relative Volume:

0.14

Market Cap:

$2.63M

Revenue:

Net Income/Loss:

$-98.30M

P/E Ratio:

-0.3329

EPS:

-7.2097

Net Cash Flow:

$-8.72M

1W Performance:

+11.11%

1M Performance:

-13.04%

6M Performance:

-68.00%

1Y Performance:

+85.33%

1-Day Range:

$2.33

$2.4799

1-Week Range:

$2.15

$2.4799

52-Week Range:

$0.541

$30.30

Zyversa Therapeutics Inc Stock (ZVSA) Company Profile

Name

Zyversa Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

908-370-5102

Address

217 W. MAIN STREET, SOMERVILLE

Employee

Twitter

Next Earnings Date

2024-08-19

Latest SEC Filings

ZVSA's Discussions on Twitter

Zyversa Therapeutics Inc Stock (ZVSA) Latest News

Sep 12, 2024

ZVSA stock touches 52-week low at $2.4 amid sharp annual decline - Investing.com UK

Sep 12, 2024

Aug 29, 2024

Thinking about buying stock in Visa Inc, Delta Air Lines, Barnes - GuruFocus.com

Aug 29, 2024

Aug 13, 2024

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Up 68.3% in July - Defense World

Aug 13, 2024

Aug 10, 2024

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update - GlobeNewswire

Aug 10, 2024

Aug 09, 2024

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update - StockTitan

Aug 09, 2024

Aug 07, 2024

ZyVersa progresses with inflammation treatment IC 100 - Investing.com

Aug 07, 2024

ZyVersa progresses with inflammation treatment IC 100 By Investing.com - Investing.com UK

Aug 07, 2024

ZyVersa Therapeutics Announces Published Data Supporting - GlobeNewswire

Aug 07, 2024

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation - Yahoo Finance

Aug 07, 2024

Aug 01, 2024

Zyversa selects lead indication for ASC inhibitor IC-100 - BioWorld Online

Aug 01, 2024

Jul 29, 2024

ZyVersa Therapeutics Announces Published Data Demonstrating - GlobeNewswire

Jul 29, 2024

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults - StockTitan

Jul 29, 2024

Jul 26, 2024

ZyVersa sets obesity as focus for new drug IC 100 By Investing.com - Investing.com Nigeria

Jul 25, 2024

Zyversa Therapeutics names lead indication for inflammasome ASC inhibitor - BioWorld Online

Jul 25, 2024

ZyVersa Therapeutics Selects Obesity and Related Metabolic - GlobeNewswire

Jul 25, 2024

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100 - Yahoo Finance

Jul 25, 2024

Jul 19, 2024

Market Momentum: ZyVersa Therapeutics Inc (ZVSA) Registers a -10.80 Decrease, Closing at 3.88 - The Dwinnex

Jul 19, 2024